AstraZeneca PLCAZN:LSE

Add to portfolio
Set alert
Interactive chart
Historical prices
Data definitions
3,383
6.50 / 0.19%
2.20m
28.05%
0.3189
Close in GBXToday's changeShares traded1 year changeBeta
As of May 17 2013 16:53 BST.Data delayed by at least 15 minutes.
Overview
Balance sheet
Cash flow
Income statement

Income statement in USD

Year on year AstraZeneca PLC's revenues fell 16.72% from 33.59bn to 27.97bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 9.98bn to 6.30bn, a 36.92% decrease. View full income statement

REVENUE
Gross margin80.78%
Net profit margin21.09%
Operating margin27.34%
NET INCOME
Return on assets11.05%
Return on equity25.88%
Return on investment15.60%

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by 31.78%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.

DIVIDEND PER SHARE
Div yield(5 year avg)0.00%
Div growth rate (5 year)8.41%
Payout ratio (TTM)61.63%
EARNINGS PER SHARE
EPS growth(5 years)5.93
EPS (TTM) vs
TTM 1 year ago		-30.267

Cash flow in USD

In 2012, AstraZeneca PLC did not generate a significant amount of cash. However, the company earned 6.95bn from its operations for a Cash Flow Margin of 24.84%. In addition the company used 1.86bn on investing activities and also paid 4.92bn in financing cash flows. View full cash flow statement

CASH FLOW
Cash flow per share5.32
Price/Cash flow per share6.39
CASH
Book value per share11.77
Tangible book value per share-1.9225

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 31.22%, a lower figure than the previous year's 34.30%. View full balance sheet

TOTAL ASSETS
Current ratio1.32
Quick ratio1.18
TOTAL DEBT
Total debt/total equity0.458
Total debt/total capital0.3122
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.